Clinical Trial Search

Primary: Overall Survival — 86; 86; 87 percentage of survival probability — p=0.95

Primary: Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1) — 4.1; 4.3 % (FEV1)

Primary: Percent Change From Baseline in BMD of the Lumbar Spine — -0.093; 0.379; -0.120 Percentage

Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16: Baseline Observation Carried Forward…

Primary: Mean Change From Baseline to Week 8 in WOMAC Pain Scale, Bioequivalence of Test to Reference. — 6.8; 6.7; 5.9 units on a scale

Primary: Number of Participants With Completion of at Least 2 Study Visits — 10; 7; 1 Participants

Primary: Number of Patients in Remission at Week 16 — 3; 14 Participants

Primary: Overall Survival (OS) — 8.57; 6.34 months — p=0.0051

Primary: Percentage of Patients With Improved Cognitive Function (The Montreal Cognitive Assessment Test Total Score of the Baseline +1 or More) — 124; 115 Participants — p=0.02

Primary: Oral Glucose Tolerance Test — 0.9 mg/dL

Primary: Overall Survival — 14.4; 15.9; 16.4 months — p=0.12

Primary: Number of Participants With First Occurrence of Target Vessel Occlusion, Surgical Revascularization, Endovascular Revascularization, Major Amputation of Target Limb…

Primary: # of Opioid Pills Consumed — 26.7; 38.4 % oxycodone used

Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination — 7.9; 2.5; 8.6; 12.7 percentage of participants

Primary: Percentage of Participants Who Achieved Clinical Remission at Week 4 — 43.7; 43.5 percentage of participants — p=0.939